This article first appeared on GuruFocus. Novo Nordisk (NVO) shares fell as much as 6% early Monday after the drugmaker outlined its long-term strategy and obesity ambitions at its Capital Markets Day in London. The company is targeting more than $23 billion in annual obesity sales by 2030 and plans to bring more than five medicines with blockbuster potential to market. It also aims to have at least five Phase 3 programs in both obesity and diabetes and other treatment areas. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart Novo Nordisk said it expects to expand oral GLP-1 capacity enough to serve 10 times more people with obesity by 2030.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.